Global Oncology Academy - Global Oncology Academy

Global Oncology Academy

Global Oncology Academy

Enhance your practice with CME
and tools that focus on the management
and treatment of patients with cancer.

Popular

Addressing Barriers to CAR T Referral in R/R LBCL
Addressing Barriers to CAR T Referral in R/R LBCL
Project Oncology®
Addressing Barriers to CAR T Referral in R/R LBCL
Steve Jackson, PharmD; Matthew J. Matasar, MD
- Steve Jackson, PharmD
- Matthew J. Matasar, MD
- Tycel Phillips, MD
Choosing Between Neoadjuvant and Perioperative Strategies in NSCLC
Choosing Between Neoadjuvant and Perioperative Strategies in NSCLC
Project Oncology®
Choosing Between Neoadjuvant and Perioperative Strategies in NSCLC
Steve Jackson, PharmD; Raghava Reddy Induru, MD
- Steve Jackson, PharmD
- Raghava Reddy Induru, MD
Epic Aura for CRC Screening: A Real-World Perspective
Epic Aura for CRC Screening: A Real-World Perspective
Clinician's Roundtable
Epic Aura for CRC Screening: A Real-World Perspective
Natalia Usoltseva MD, FACP, MHA
- Natalia Usoltseva MD, FACP, MHA
Improving CRC Screening Conversations in Primary Care
Improving CRC Screening Conversations in Primary Care
Clinician's Roundtable
Improving CRC Screening Conversations in Primary Care
Natalia Usoltseva MD, FACP, MHA
- Natalia Usoltseva MD, FACP, MHA
Improving CRC Screening Workflows: A PCP's Recommendations
Improving CRC Screening Workflows: A PCP's Recommendations
Clinician's Roundtable
Improving CRC Screening Workflows: A PCP's Recommendations
Natalia Usoltseva MD, FACP, MHA
- Natalia Usoltseva MD, FACP, MHA
Brain Metastases Management: From Detection to Multidisciplinary Care
Brain Metastases Management: From Detection to Multidisciplinary Care
MinuteCE®
Brain Metastases Management: From Detection to Multidisciplinary Care
Barbara O'Brien, MD
1.00 program credit
- Barbara O'Brien, MD
1.00 program credit
Decision in Context: A Practical Framework for Sequencing Systemic and CNS Therapies in Brain Metastases
Decision in Context: A Practical Framework for Sequencing Systemic and CNS Therapies in Brain Metastases
CME/CE
Decision in Context: A Practical Framework for Sequencing Systemic and CNS Therapies in Brain Metastases
Barbara O'Brien, MD
0.25 credits
- Barbara O'Brien, MD
0.25 credits
HER2+ Breast Cancer With Brain Metastases: Rethinking First-Line Treatment in the ADC Era
HER2+ Breast Cancer With Brain Metastases: Rethinking First-Line Treatment in the ADC Era
MinuteCE®
HER2+ Breast Cancer With Brain Metastases: Rethinking First-Line Treatment in the ADC Era
Barbara O'Brien, MD; Nadia Harbeck, MD, PhD
1.00 program credit
- Barbara O'Brien, MD
- Nadia Harbeck, MD, PhD
1.00 program credit

Medical News

Medical News
Real-World Use of a 1021-Gene Liquid Biopsy Assay
05/14/2026
Read more
Medical News
AI-Assisted Colorectal Lesion Detection Falls Short In Private Practice Trial
05/12/2026
Read more
Medical News
Metal Stent Drainage vs Early Surgery in Pancreatic Cancer
05/12/2026
Read more
Medical News
Extended Endocrine Therapy and Breast Cancer Subtype
05/11/2026
Read more

CME/CE

Improving Quality Care Across the Spectrum of HER2 Expression in HR+ Metastatic Breast Cancers: Practice Changes to Improve Care
Improving Quality Care Across the Spectrum of HER2 Expression in HR+ Metastatic Breast Cancers: Practice Changes to Improve Care
CME/CE
Improving Quality Care Across the Spectrum of HER2 Expression in HR+ Metastatic Breast Cancers: Practice Changes to Improve Care
Joseph Kim, MD, MPH, MBA, FACHE; Samir Dalia, MD
0.25 credits
- Joseph Kim, MD, MPH, MBA, FACHE
- Samir Dalia, MD
- Christopher Jurief
0.25 credits
Redefining Immunotherapy Access: Integrating Subcutaneous Checkpoint Inhibitors Across Solid Tumors
Redefining Immunotherapy Access: Integrating Subcutaneous Checkpoint Inhibitors Across Solid Tumors
CME/CE
Redefining Immunotherapy Access: Integrating Subcutaneous Checkpoint Inhibitors Across Solid Tumors
Enriqueta Felip, MD; Kristi Orbaugh, MSN, RNP, AOCN
0.25 credits
- Enriqueta Felip, MD
- Kristi Orbaugh, MSN, RNP, AOCN
0.25 credits
First-Line Management of HR+/HER2-Low Breast Cancer With Brain Metastases
First-Line Management of HR+/HER2-Low Breast Cancer With Brain Metastases
MinuteCE®
First-Line Management of HR+/HER2-Low Breast Cancer With Brain Metastases
Barbara O'Brien, MD; Nadia Harbeck, MD, PhD
1.00 program credit
- Barbara O'Brien, MD
- Nadia Harbeck, MD, PhD
1.00 program credit
Managing Brain Metastases Through Multidisciplinary Team Collaboration
Managing Brain Metastases Through Multidisciplinary Team Collaboration
MinuteCE®
Managing Brain Metastases Through Multidisciplinary Team Collaboration
Benjamin Levy, MD
1.00 program credit
- Benjamin Levy, MD
1.00 program credit

Clinical Practice

Coordinating Care for mCSPC Patients Receiving Androgen Receptor Pathway Inhibitors
Coordinating Care for mCSPC Patients Receiving Androgen Receptor Pathway Inhibitors
Project Oncology®
Coordinating Care for mCSPC Patients Receiving Androgen Receptor Pathway Inhibitors
Charles Turck, PharmD, BCPS, BCCCP; Daniel Geynisman, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Daniel Geynisman, MD
- Jonathan Henderson, MD
Blood-Based Colorectal Cancer Screening: Where Do We Stand?
Blood-Based Colorectal Cancer Screening: Where Do We Stand?
Clinician's Roundtable
Blood-Based Colorectal Cancer Screening: Where Do We Stand?
Peter Buch, MD, FACG, AGAF, FACP; Aasma Shaukat, MD, MPH
- Peter Buch, MD, FACG, AGAF, FACP
- Aasma Shaukat, MD, MPH
Choosing the Right ARPI in Metastatic Castration-Sensitive Prostate Cancer
Choosing the Right ARPI in Metastatic Castration-Sensitive Prostate Cancer
Project Oncology®
Choosing the Right ARPI in Metastatic Castration-Sensitive Prostate Cancer
Brian P. McDonough, MD, FAAFP; Bilal Siddiqui, MD
- Brian P. McDonough, MD, FAAFP
- Bilal Siddiqui, MD
Managing AKT Inhibitor-Associated AEs in HR+/HER2- Advanced Breast Cancer
Managing AKT Inhibitor-Associated AEs in HR+/HER2- Advanced Breast Cancer
Project Oncology®
Managing AKT Inhibitor-Associated AEs in HR+/HER2- Advanced Breast Cancer
Charles Turck, PharmD, BCPS, BCCCP; Neil M. Iyengar, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Neil M. Iyengar, MD
- Sarah H. Donahue, MPH, NP

Programs

Urinary and Circulating Tumor DNA in Muscle-Invasive Bladder Cancer: NIAGARA Data
Urinary and Circulating Tumor DNA in Muscle-Invasive Bladder Cancer: NIAGARA Data
Project Oncology®
Urinary and Circulating Tumor DNA in Muscle-Invasive Bladder Cancer: NIAGARA Data
Charles Turck, PharmD, BCPS, BCCCP; Petros Grivas, MD, PhD
- Charles Turck, PharmD, BCPS, BCCCP
- Petros Grivas, MD, PhD
Sequencing Systemic and Local Therapy in HER2-Overexpressing Metastatic NSCLC 
Sequencing Systemic and Local Therapy in HER2-Overexpressing Metastatic NSCLC 
MinuteCE®
Sequencing Systemic and Local Therapy in HER2-Overexpressing Metastatic NSCLC 
Benjamin Levy, MD; Melin Khandekar, MD, PhD
1.00 program credit
- Benjamin Levy, MD
- Melin Khandekar, MD, PhD
1.00 program credit
CME/CE In-Person & Virtual Event
Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
May 30, 2026
Chicago, Illinois
1.50 credits
Making Mechanism-Based Treatment Decisions in cGVHD
Making Mechanism-Based Treatment Decisions in cGVHD
Project Oncology®
Making Mechanism-Based Treatment Decisions in cGVHD
Brian P. McDonough, MD, FAAFP; Alicia Lieberman, MD, MS
- Brian P. McDonough, MD, FAAFP
- Alicia Lieberman, MD, MS